YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558)
HKEX:1558
Hong Kong Market
Holding HK:1558?
Track your performance easily

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (1558) Stock Price & Analysis

0 Followers

1558 Stock Chart & Stats


Options Prices

Currently, No data available
---

Ownership Overview

0.00%2.23%2.80%94.97%
0.00%
Insiders
2.80% Other Institutional Investors
94.97% Public Companies and
Individual Investors

1558 FAQ

What was YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s price range in the past 12 months?
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H lowest stock price was HK$6.14 and its highest was HK$13.30 in the past 12 months.
    What is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s market cap?
    Currently, no data Available
    When is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s upcoming earnings report date?
    YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s upcoming earnings report date is Mar 21, 2025 which is in 182 days.
      How were YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s earnings last quarter?
      YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H released its earnings results on Aug 30, 2024. The company reported HK$0.857 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.857.
        Is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H overvalued?
        According to Wall Street analysts YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H pay dividends?
          YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H pays a Annually dividend of HK$0.11 which represents an annual dividend yield of N/A. See more information on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H dividends here
            What is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s EPS estimate?
            YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H have?
            YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H has 653,767,700 shares outstanding.
              What happened to YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s price movement after its last earnings report?
              YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H reported an EPS of HK$0.857 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.17%.
                Which hedge fund is a major shareholder of YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H?
                Currently, no hedge funds are holding shares in HK:1558
                ---

                YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Stock Smart Score

                10
                Unlock Smart Score
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Company Description

                YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H

                Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic and cardiovascular diseases. The company's major revenue driver is the anti-viral product division, which manufactures its key product, Kewei. It is one of the leading products in China's anti-influenza market. Its other products include Ertongshu, Oumeining, Xinhaining, and Xining which cure diseases such as hypertension and allergy.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Viva Biotech Holdings
                China Boqi Environmental (Holding) Co., Ltd.
                Hansoh Pharmaceutical Group Company Limited

                Best Analysts Covering 1558

                1 Year
                Laurence TamMorgan Stanley
                1 Year Success Rate
                1/1 ratings generated profit
                100%
                1 Year Average Return
                +0.90%
                reiterated a buy rating 3 days ago
                Copying Laurence Tam's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +0.90% per trade.
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis